Double Materiality Assessment

In 2023, we performed a robust double materiality assessment to identify our priority corporate responsibility topics. The assessment considers our impact on society and the environment as well as how corporate responsibility risks and opportunities may impact our business. We interviewed Regeneron's executive team, conducted an employee survey and engaged our stakeholders, including investors, collaborators, suppliers, patient groups and nonprofit organizations. The assessment was also informed by big data analysis. The findings, summarized here, were reviewed by the Board's Corporate Governance and Compliance Committee. These findings are also informing our future responsibility strategy and goals, which we plan to share in our 2025 Responsibility Report. Materiality of topics may change as our business and operational landscapes continue to evolve.



Impact on Regeneron's Business Value

Environmental Topic

Social Topic

Governance Topic

Double Materiality Topic Definitions

SOCIAL Topics	DEFINITION	ENVIRONMENTAL TOPICS	DEFINITION	GOVERNANCE TOPICS	DEFINITION
Clinical Trial Practices	Ensuring safe and ethical treatment of participants, informed consent, equitable access, diverse enrollment, transparent reporting and regulatory compliance in clinical trials.	Biodiversity	Maintenance of biodiversity (e.g., living organisms in an area, encompassing different species, genetic diversity and ecosystems), including impacts resulting from raw material sourcing, land use change (e.g., construction) and water use.	Animal Welfare	Ethics related to the use of animals to assess the safe and efficacy of potential medical products.
Community Impact	Contributions to the local communities where the company operates, including economic development, educational opportunities and philanthropy.			Compliance Practices	 Efforts to maintain a culture of ethics and integrity, including compliance with anti-bribery, anti-corruption antitrust and fair competition, and all other applicable laws and regulations Including associated reporting mechanisms and remediation efforts. Maintaining high-quality corporate governance policie and practices, including areas such as Board compos and effectiveness, oversight of management, executive compensation and succession planning.
Representation in the Workplace	Equal and fair treatment and opportunities, fostering a welcoming culture of mutual respect among colleagues.	Climate Change Impacts	Physical risks (e.g., extreme weather, flooding, drought, rising temperatures) and transition risks (e.g., stakeholder expectations, regulations, prices, energy availability) of climate change across operations and value chain.	Corporate Governance	
Ethical Use of Emerging Technology	Ethical aspects of using genetic/biologic material (e.g., stem cell research) and advanced technologies such as AI and machine learning			•	
Access and Affordability	Facilitate access to high-quality, affordable medicines and medical services for people who need them.	Energy and GHG Emissions	Energy consumption, including energy efficiency and renewable energy adoption throughout operations and supply chain. GHG emissions (e.g., carbon dioxide, methane, nitrous oxide) from business operations and value chain activities that contribute to climate change, including emissions from energy use, transportation, refrigeration and purchasing.	Cybersecurity and Data Privacy	Protecting computer systems, devices, networks and data from unauthorized access, attacks and disruption ensuring their confidentiality, integrity and availability. The protection of personal information, including handling, storage and usage of data, to safeguard individual privacy rights of employees, patients, payer and other relevant stakeholders.
Health Outcomes	Efforts to enhance disease prevention, disease awareness and adherence to treatment to improve patients' health and wellbeing.				
Occupational Health and Safety	Respect for workers' rights to life, health, and safety and minimizing workers' exposure to potential health and safety hazards.	Environmental Impact of Products	 Product impacts on natural resources and ecosystems throughout their lifecycle, including impacts resulting from extraction and use of raw materials, production of product delivery apparatuses (e.g., autoinjectors, syringes) and packaging and impacts related to disposal of products and packaging. Hazardous (e.g., chemicals, biohazardous materials) and non-hazardous (e.g., plastics, food scraps) waste disposal and generation across the value chain, including R&D, manufacturing and supply chain. 	Political Advocacy	Ethics related to political engagement and public poli activities, including approach to lobbying, political contributions and disclosure
Product Quality and Patient Safety	Ensuring product quality, safety and regulatory compliance through robust protocols, defect prevention, risk management and effective safety measures.			Responsible Sales and Marketing	Fair, transparent and compliant marketing and promo of our products and services that enable patients and HCPs to make informed decisions.
Scientific Research and Innovation	R&D and innovation to create needed new medicines for patients, inclusive of protecting intellectual property rights to facilitate continued innovation, protect patients and	Waste			
STEM Talent Pipeline	Fostering the next generation of STEM talent to ensure a diverse and deep pool of scientific innovators.			Supply Chain Management	Management systems and processes that ensure supplier reliability, continuity of supply, quality assura supplier diversity, fair relations and due diligence on adverse impacts.
Talent Attraction and Retention	Ability to recruit and engage employees with skill sets required for the current and future success of the business, with focus on areas such as training and development, compensation and employee well-being.	Water	Water withdrawals and discharges from business operations, including wastewater.	Tax Practices	Approach to taxation that is efficient, transparent and compliant with domestic and international laws.





assurance,

ent and